Cover Image
市場調查報告書

HDAC (組蛋白去乙醯酵素) 抑制劑市場

HDAC Inhibitors Market, 2016 - 2026

出版商 ROOTS ANALYSIS 商品編碼 367978
出版日期 內容資訊 英文 233 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
HDAC (組蛋白去乙醯酵素) 抑制劑市場 HDAC Inhibitors Market, 2016 - 2026
出版日期: 2016年08月19日 內容資訊: 英文 233 Pages
簡介

本報告以HDAC (組蛋白去乙醯酵素) 抑制劑的市場為焦點,提供開發中產品的目前形勢與未來展望的相關調查,已上市、開發中 (第三階段、第二階段) 藥物的銷售量預測,各治療領域、種類特異性、臨床試驗指標的臨床考察,發表分析,及社群媒體的趨勢等彙整資料。

第1章 序文

第2章 摘要整理

第3章 簡介

  • 分子生物學、細胞週期的中心法則
  • DNA:結構與機能
  • 表觀遺傳學基本面
  • 組蛋白去乙醯酵素 (HDAC)
  • HDAC抑制劑

第4章 HDAC抑制劑:市場形勢

  • 本章概要
  • HDAC抑制劑的開發平台
  • 分佈:各開發相位
  • 分佈:各治療領域
  • 分佈:各級特異性
  • 分佈:開發者的各類型
  • 分佈:各地區
  • 活躍的企業

第5章 藥物簡介:已上市、後期開發階段的HDAC抑制劑

  • 本章概要
  • 企業、藥物簡介:已上市、第三階段分子
    • Celgene Corporation
    • Onxeo
    • Novartis
    • Shenzhen Chipscreen Biosciences
    • Syndax Pharmaceuticals
  • 藥物簡介:第二階段分子
    • Abexinostat (PCI-24781)
    • CUDC-907
    • FRM-0334 (EVP-0334)
    • Givinostat (ITF2357)
    • Mocetinostat (MGCD103)
    • Pracinostat (SB939)
    • Resminostat (4SC-201)
    • SFX-01
    • SHAPE (SHP-141)
    • Tefinostat (CHR-2845)

第6章 重要考察:治療領域、級特異性、臨床試驗指標

  • 臨床開發分析:級特異性、治療領域
  • 臨床開發分析:開發者形勢
  • 臨床開發分析:臨床實驗試驗指標比較

第7章 市場預測、機會分析

  • 本章概要
  • 範圍、限制
  • 預測手法
  • HDAC抑制劑整體市場
  • HDAC抑制劑市場:個別預測

第8章 發表分析

  • 本章概要
  • HDAC抑制劑:發表
  • 發表分析:季分佈
  • 發表分析:HDAC抑制劑各級的分佈
  • 發表分析:各研究藥物的分佈
  • 發表分析:各治療領域的分佈
  • 發表分析:各日誌的分佈
  • 發表分析:各開發相位的分佈
  • 發表分析:各治療類型的分佈

第9章 社群媒體:新興趨勢

  • 本章概要
    • Twitter上的趨勢
    • Facebook上的趨勢

第10章 結論

  • 開發的前臨床階段的幾個分子的開發平台順利
  • HDAC抑制劑目標疾病領域廣泛的領域
  • 種類特異性HDAC抑制劑更鎖定標的方法檢討
  • 產業、非產業企業雙方慢慢興趣高漲
  • 受穩定的前臨床開發平台支撐,預計HDAC抑制劑將成為數十億美元市場

第11章 採訪

第12章 附錄1:圖表

第13章 附錄2:企業清單

圖表清單

目錄
Product Code: RA10064

Epigenetics is defined as a heritable change in the gene expression and its activity without alteration in the DNA sequence. The different epigenetic mechanisms through which gene expression can be modulated primarily include histone modification, DNA methylation, alteration of chromatin architecture and involvement of small-interfering or non-coding RNAs. Enzymes such as histone acetyltransferases (HATs), histone methyltransferases (HMTs), histone deacetylases (HDACs) and histone demethylases (DMTs) play significant role in epigenetic regulation. HATs and HDACs are the two major enzyme classes involved in post-translational modification of N-terminal tail of the histone proteins; HATs are responsible for acetylation of N-terminal histone tail whereas HDACs possess an opposite mode of action and act by removing the attached acetyl group.

Currently, HDACs are widely being studied as a promising therapeutic target. HDAC inhibitors can be classified into four main categories based on the structural characteristics of the Zn2+ binding domain. These include hydroxamic acids, cyclic peptides, short-chain fatty acids and benzamides. In addition to the synthetic HDAC inhibitors, the HDAC inhibitory role of various naturally occurring molecules has recently been discovered. These include molecules such as curcumin, depudecin, flavone and taipoxin.

There are five commercialized HDAC inhibitors, majority of which are primarily targeting hematological malignancies. Approval of the first HDAC inhibitor, Zolinza™(vorinostat), in 2006 for treatment of CTCL gave the market an initial impetus. The momentum was carried on by the other molecules that were marketed in 2009 (Istodax®), 2014 (Beleodaq®, Epidaza®) and 2015 (Farydak®). These drugs are currently being evaluated for several other indications as a single agent or as a combination therapy in lower stages of development.

Synopsis:

The “HDAC Inhibitors Market, 2016-2026” report was commissioned to examine the current landscape and the future outlook of the growing pipeline of products in this area. HDACs have been studied in cellular processes such as apoptosis, autophagy, metabolism, DNA damage repair, cell cycle control and senescence. Altered expression of HDACs has been observed in different tumors; this makes them a potential target for treatment of cancer and other genetic or epigenetic related disorders. Inhibition of HDACs has shown positive results in disruption of multiple cell signaling pathways and prevention of tumor growth.

The HDAC inhibitors market has steadily evolved over the last few years with many drug candidates designed to address a wide range of oncological and non-oncological disorders. With five commercialized products, the market has gained attention from several industry and non-industry players. Initially, the market was led by big pharma players; however, the success of the marketed products has encouraged several start-ups and mid-sized firms to step into this lucrative space. We identified around 21 start-ups and 14 mid-sized companies that are exploring the opportunities presented by HDAC inhibitors. Currently, the HDAC inhibitors' pipeline comprises of over 90 molecules under development. It is worth highlighting that over the last few years, the focus has shifted from pan-HDAC to class-specific HDAC inhibitors. Additionally, the research activity, with respect to the number of publications, has been highly promising. With an intense research framework, there have been over 9500 papers published in the last 10 years (as captured in PubMed). Further, increasing popularity on social media validates the growing interest in this field. The analysis conducted from 2009 to 2015 demonstrates a Compound Annual Growth Rate (CAGR) of 33% in the tweets registered on Twitter. Similar trends have been observed on Facebook.

As pharmaceutical companies continue to initiate and expand their research programs in this area, one of the key objectives outlined for this report was to understand the future potential of the market. This was done by analyzing:

  • The HDAC inhibitor pipeline (marketed, clinical and preclinical drugs) in terms of phase of development, HDAC class specificity and the evolving therapeutic areas / target indications.
  • The likely adoption of the HDAC inhibitors by understanding the competition posed by the current treatment regime in the coming few years.
  • The emerging trends and the popularity of HDAC inhibitors on social media such as Twitter and Facebook over the last few years.
  • The research activity in this field in terms of the focus of the publications / research articles granted across the globe in the last two years.

The study provides a detailed market forecast and opportunity analysis for the time period 2016-2026. The research, analysis and insights presented in this report include potential sales of the approved drugs and the ones in late stages of development (phase III and phase II). To add robustness to our model, we have provided three scenarios for our market forecast; these include the conservative, base and optimistic scenarios. Our opinions and insights, presented in this study were influenced by several discussions we conducted with experts in this area. All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Example Highlights

  • 1. Nearly 90 HDAC inhibitors are currently in clinical / preclinical stages of development; the clinical molecules account for over 30% of the pipeline while over 60% is captured by molecules in the preclinical / discovery stage.
  • 2. With 66% of the pipeline molecules targeting oncological indications, cancer remains one of the most widely studied field for HDAC inhibitors. Within oncology, hematological malignancies such as PTCL and CTCL are popular targets; three HDAC inhibitors (Zolinza™, ISTODAX® and BELEODAQ®) are approved for these indications. Other therapeutic areas such as autoimmune disorders, infectious diseases, inflammatory disorders, neurological disorders, are also gradually gaining traction.
  • 3. Although the market was initially led by the large-size pharma players (such as Celgene, Merck, Novartis), the current market is characterized by the presence of several small / mid-sized pharma players. Notable examples of the small and mid-sized firms include 4SC, Chroma Therapeutics, CrystalGenomics, Curis, Evgen Pharma, FORUM Pharmaceuticals, Karus Therapeutics, Mirati Therapeutics, MEI Pharma, Shenzhen Chipscreen Biosciences, Syndax Pharmaceuticals and TetraLogic Pharmaceuticals.
  • 4. In addition, there are several non-industry institutes and universities that are primarily carrying out preclinical research. Examples of these include Harvard Medical School (BG45), Imperial College London (C1A), Kyoto University (Jδ, Sδ), National Taiwan University (Quinazolin-4-one derivatives), Taipei Medical University (MPT0E028), University of Messina (MC-1575, MC-1568).
  • 5. Four of the five approved drugs are pan-HDAC inhibitors targeting HDAC isoforms non-specifically. However, in the past few years, several class selective HDAC inhibitors have entered the clinic; these are associated with a higher efficacy and result in decreased toxicity from the treatment. Of the total HDAC inhibitors identified, 52% of the molecules are class specific; of these, 33% molecules target Class I specific isoforms and the rest target Class II specific isoforms of HDACs. Notable examples of molecules targeting class-specific HDACs includeentinostat (phase III), resminostat (phase II), SHP-141 (phase II), mocetinostat (phase II), CHR-3996 (phase I/II) and ricolinostat (phase I/II).
  • 6. The HDAC inhibitors market is expected to grow at a healthy annual rate of 32% over the next decade.With multiple potential target indications, Istodax® is expected to capture the largest market share (close to 21%) in 2026, followed by entinostat, Farydak® and Beleodaq®.

Research Methodology

Most of the data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analyst's views

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Chapter Outlines

Chapter 2 provides an executive summary of the report. It offers a high level view on where the HDAC inhibitors market is headed in the mid to long term.

Chapter 3 explains the central dogma of molecular biology and fundamentals of epigenetics. It elaborates on the effects of histone modifications such as methylation, acetylation, phosphorylation, ubiquitination and sumoylation on the biological processes such as DNA replication, transcription and repair. Additionally, the chapter highlights the classification of HDACs and HDAC inhibitors and discusses the specific role of HDAC inhibition in regulation of various biological processes. The chapter also provides an overview of the various disease indications across multiple therapeutic areas being targeted by HDAC inhibitors.

Chapter 4 includes information on over 90 molecules that are either approved or are being evaluated in different stages of development (clinical and preclinical/discovery). We have identified the companies that are active in this market and conducted a detailed pipeline analysis highlighting the most commonly targeted indications, target classes of HDAC, phases of development and specific geographical pockets where innovation is mostly concentrated.

Chapter 5 provides comprehensive profiles of the marketed, phase III and phase II drug candidates with a detailed understanding on the drug specification, mechanism of action, clinical development status, key clinical trial results, collaborations and overview of sponsors.

Chapter 6 presents key insights on HDAC inhibitors. It provides a schematic representation highlighting the distribution of HDAC inhibitors by target class, therapeutic area and highest phase of development. The chapter presents the landscape of industrial and non-industrial developers of HDAC inhibitors. Additionally, it presents a detailed comparative analysis on the key clinical trial endpoints for drugs that are marketed or in phase III and phase II of development.

Chapter 7 highlights the sales forecast and the associated monetary opportunity offered by this class of drugs. We have provided detailed insights covering target patient population, likely price points and the adoption rates of marketed, phase III and phase II HDAC inhibitors.

Chapter 8 presents publication analysis of the articles published on HDAC inhibitors in PubMed over the last two years. The chapter covers some important aspects of these publications such as the most studied disease areas, phase of the study and the drug combinations under investigation.

Chapter 9 provides the emerging trends on social media related to HDAC inhibitors. It presents an overview of the popularity of the keywords histone deacetylase inhibitor and HDAC inhibitor on Twitter and Facebook from 2009 to 2015.

Chapter 10 summarizes the overall report. In this chapter, we provide a recap of the key takeaways and our independent opinion based on the research and analysis described in previous chapters.

Chapter 11 is a collection of interview transcripts of the discussions that were held with key stakeholders in this market. We have presented the details provided to us by Dr. Simon Kerry (CEO of Karus Therapeutics), Dr. James Christensen (CSO and Senior VP of Mirati Therapeutics) and Dr. Hyung J. Chun (Associate Professor of Medicine, Yale School of Medicine)

Chapter 12 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 13 is an appendix, which provides the list of companies and organizations mentioned in the report.

Table of Contents

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. The Central Dogma of Molecular Biology and Cell Cycle
  • 3.2. DNA: Structure and Functions
  • 3.3. Fundamentals of Epigenetics
    • 3.3.1. Effect of Histone Modification on DNA Based Processes
    • 3.3.2. Chromatin Structure Modification and its Enzymes
  • 3.4. Histone Deacetylases (HDACs)
    • 3.4.1. Classification of HDACs
    • 3.4.2. Role of HDACs and HDAC Inhibitors in Cellular Processes
  • 3.5. HDAC Inhibitors
    • 3.5.1. Structure and Classification
    • 3.5.2. Different Types of HDAC Inhibitors
    • 3.5.3. Therapeutic Applications of HDAC Inhibitors

4. HDAC INHIBITORS: MARKET LANDSCAPE

  • 4.1. Chapter Overview
  • 4.2. Development Pipeline of HDAC Inhibitors
  • 4.3. Distribution by Phase of Development
  • 4.4. Distribution by Therapeutic Area
  • 4.5. Distribution by Class Specificity
  • 4.6. Distribution by Type of Developer
  • 4.7. Distribution by Geography
  • 4.8. Active Industry Players

5. DRUG PROFILES: MARKETED AND LATE-STAGE HDAC INHIBITORS

  • 5.1. Chapter Overview
  • 5.2. Company and Drug Profiles: Marketed and Phase III Molecules
    • 5.2.1. Celgene Corporation
      • 5.2.1.1. Company Overview
      • 5.2.1.2. Financial Information
      • 5.2.1.3. Product Profile: Istodax® (Romidepsin)
        • 5.2.1.3.1. Drug Specifications
        • 5.2.1.3.2. Mechanism of Action
        • 5.2.1.3.3. Current Status of Development
        • 5.2.1.3.4. Clinical Studies
        • 5.2.1.3.5. Key Clinical Trial Results
        • 5.2.1.3.6. Dosage Regimen, Manufacturing and Sales
    • 5.2.2. Onxeo
      • 5.2.2.1. Company Overview
      • 5.2.2.2. Financial Information
      • 5.2.2.3. Product Profile: Beleodaq® (Belinostat / PXD101)
        • 5.2.2.3.1. Drug Specifications
        • 5.2.2.3.2. Mechanism of Action
        • 5.2.2.3.3. Current Status of Development
        • 5.2.2.3.4. Clinical Studies
        • 5.2.2.3.5. Key Clinical Trial Results
        • 5.2.2.3.6. Dosage Regimen and Sales
        • 5.2.2.3.7. Collaborations
    • 5.2.3. Novartis
      • 5.2.3.1. Company Overview
      • 5.2.3.2. Financial Performance
      • 5.2.3.3. Product Profile: Farydak® (Panobinostat / LBH589)
        • 5.2.3.3.1. Drug Specifications
        • 5.2.3.3.2. Mechanism of Action
        • 5.2.3.3.3. Current Status of Development
        • 5.2.3.3.4. Clinical Studies
        • 5.2.3.3.5. Key Clinical Trial Results
        • 5.2.3.3.6. Dosage Regimen
    • 5.2.4. Shenzhen Chipscreen Biosciences
      • 5.2.4.1. Company Overview
      • 5.2.4.2. Product Profile: Epidaza® (Chidamide)
        • 5.2.4.2.1. Drug Specifications
        • 5.2.4.2.2. Mechanism of Action
        • 5.2.4.2.3. Current Status of Development
        • 5.2.4.2.4. Clinical Studies
        • 5.2.4.2.5. Key Clinical Trial Results
        • 5.2.4.2.6. Collaborations
    • 5.2.5. Syndax Pharmaceuticals
      • 5.2.5.1. Company Overview
      • 5.2.5.2. Product Profile: Entinostat (SNDX-275 / MS-275)
        • 5.2.5.2.1. Drug Specifications
        • 5.2.5.2.2. Mechanism of Action
        • 5.2.5.2.3. Current Status of Development
        • 5.2.5.2.4. Clinical Studies
        • 5.2.5.2.5. Key Clinical Trial Results
        • 5.2.5.2.6. Collaborations
  • 5.3. Drug Profiles: Phase II Molecules
    • 5.3.1. Abexinostat (PCI-24781)
      • 5.3.1.1. Drug Specifications and Mechanism of Action
      • 5.3.1.2. Current Status of Development
      • 5.3.1.3. Clinical Studies
      • 5.3.1.4. Key Clinical Trial Results
      • 5.3.1.5. Collaborations
    • 5.3.2. CUDC-907
      • 5.3.2.1. Drug Specifications and Mechanism of Action
      • 5.3.2.2. Current Status of Development
      • 5.3.2.3. Clinical Studies
      • 5.3.2.4. Key Clinical Trial Results
      • 5.3.2.5. Collaborations
    • 5.3.3. FRM-0334 (EVP-0334)
      • 5.3.3.1. Drug Specifications and Mechanism of Action
      • 5.3.3.2. Current Status of Development
      • 5.3.3.3. Clinical Studies
      • 5.3.3.4. Collaborations
    • 5.3.4. Givinostat (ITF2357)
      • 5.3.4.1. Drug Specifications and Mechanism of Action
      • 5.3.4.2. Current Status of Development
      • 5.3.4.3. Clinical Studies
      • 5.3.4.4. Key Clinical Trial Results
      • 5.3.4.5. Collaborations
    • 5.3.5. Mocetinostat (MGCD103)
      • 5.3.5.1. Drug Specifications and Mechanism of Action
      • 5.3.5.2. Current Status of Development
      • 5.3.5.3. Clinical Studies
      • 5.3.5.4. Key Clinical Trial Results
      • 5.3.5.5. Collaborations
    • 5.3.6. Pracinostat (SB939)
      • 5.3.6.1. Drug Specifications and Mechanism of Action
      • 5.3.6.2. Current Status of Development
      • 5.3.6.3. Clinical Studies
      • 5.3.6.4. Key Clinical Trial Results
      • 5.3.6.5. Collaborations
    • 5.3.7. Resminostat (4SC-201)
      • 5.3.7.1. Drug Specifications and Mechanism of Action
      • 5.3.7.2. Current Status of Development
      • 5.3.7.3. Clinical Studies
      • 5.3.7.4. Key Clinical Trial Results
      • 5.3.7.6. Collaborations
    • 5.3.8. SFX-01
      • 5.3.8.1. Drug Specifications and Mechanism of Action
      • 5.3.8.2. Current Status of Development
      • 5.3.8.3. Clinical Studies
      • 5.3.8.4. Collaborations
    • 5.3.9. SHAPE (SHP-141)
      • 5.3.9.1. Drug Specifications and Mechanism of Action
      • 5.3.9.2. Current Status of Development
      • 5.3.9.3. Clinical Studies
      • 5.3.9.4. Key Clinical Trial Results
      • 5.3.9.5. Collaborations
    • 5.3.10. Tefinostat (CHR-2845)
      • 5.3.10.1. Drug Specifications and Mechanism of Action
      • 5.3.10.2. Current Status of Development
      • 5.3.10.3. Clinical Studies
      • 5.3.10.4. Key Clinical Trial Results

6. KEY INSIGHTS: THERAPEUTIC AREA, CLASS SPECIFICITY, CLINICAL ENDPOINTS

  • 6.1. Clinical Development Analysis: Class Specificity and Therapeutic Areas
  • 6.2. Clinical Development Analysis: Developer Landscape
  • 6.3. Clinical Development Analysis: Trial Endpoint Comparison

7. MARKET FORECAST AND OPPORTUNITY ANALYSIS

  • 7.1. Chapter Overview
  • 7.2. Scope and Limitations
  • 7.3. Forecast Methodology
  • 7.4. Overall HDAC Inhibitors Market
  • 7.5. HDAC Inhibitors Market: Individual Forecasts
    • 7.5.1. Zolinza™ (Merck)
    • 7.5.2. Istodax® (Celgene Corporation)
      • 7.5.2.1. Target Patient Population
      • 7.5.2.2. Sales Forecast
    • 7.5.3. Beleodaq® (Onxeo)
      • 7.5.3.1. Target Patient Population
      • 7.5.3.2. Sales Forecast
    • 7.5.4. Farydak® (Novartis)
      • 7.5.4.1. Target Patient Population
      • 7.5.4.2. Sales Forecast
    • 7.5.5. Epidaza® (Shenzhen Chipscreen Biosciences)
      • 7.5.5.1. Target Patient Population
      • 7.5.5.2. Sales Forecast
    • 7.5.6. Entinostat (Syndax Pharmaceuticals)
      • 7.5.6.1. Target Patient Population
      • 7.5.6.2. Sales Forecast
    • 7.5.7. Abexinostat (Pharmacyclics)
      • 7.5.7.1. Target Patient Population
      • 7.5.7.2. Sales Forecast
    • 7.5.8. CUDC-907 (Curis)
      • 7.5.8.1. Target Patient Population
      • 7.5.8.2. Sales Forecast
    • 7.5.9. FRM-0334 (FORUM Pharmaceuticals)
      • 7.5.9.1. Target Patient Population
      • 7.5.9.2. Sales Forecast
    • 7.5.10. Mocetinostat (Mirati Therapeutics)
      • 7.5.10.1. Target Patient Population
      • 7.5.10.2. Sales Forecast
    • 7.5.11. Pracinostat (MEI Pharma)
      • 7.5.11.1. Target Patient Population
      • 7.5.11.2. Sales Forecast
    • 7.5.12. Resminostat (4SC, Menarini, Yakult Honsha)
      • 7.5.12.1. Target Patient Population
      • 7.5.12.2. Sales Forecast
    • 7.5.13. SFX-01 (Evgen Pharma)
      • 7.5.13.1. Target Patient Population
      • 7.5.13.2. Sales Forecast
    • 7.5.14. SHP-141 (TetraLogic Pharmaceuticals)
      • 7.5.14.1. Target Patient Population
      • 7.5.14.2. Sales Forecast
    • 7.5.15. Tefinostat (Chroma Therapeutics)
      • 7.5.15.1. Target Patient Population
      • 7.5.15.2. Sales Forecast

8. PUBLICATION ANALYSIS

  • 8.1. Chapter Overview
  • 8.2. HDAC Inhibitors: Publications
  • 8.3. Publication Analysis: Quarterly Distribution
  • 8.4. Publication Analysis: Distribution by HDAC Inhibitor Class
  • 8.5. Publication Analysis: Distribution by Drugs Studied
  • 8.6. Publication Analysis: Distribution by Therapeutic Area
  • 8.7. Publication Analysis: Distribution by Journals
  • 8.8. Publication Analysis: Distribution by Phase of Development
  • 8.9. Publication Analysis: Distribution by Type of Therapy

9. SOCIAL MEDIA: EMERGING TRENDS

  • 9.1. Chapter Overview
    • 9.1.1. Trends on Twitter
    • 9.1.2. Trends on Facebook

10. CONCLUSION

  • 10.1. The Pipeline is Healthy with Several Molecules in Preclinical Stages of Development
  • 10.2. HDAC Inhibitors Cater to a Wide Spectrum of Disease Areas
  • 10.3. Class Specific HDAC Inhibitors Have Been Explored for a More Targeted Approach
  • 10.4. The Interest is Gradually Rising Amongst Both Industry and Non-Industry Players
  • 10.5. Supported by a Robust Preclinical Pipeline, HDAC Inhibitors are Expected to Emerge as A Multi-Billion Dollar Market

11. INTERVIEW TRANSCRIPTS

  • 11.1. Chapter Overview
  • 11.2. Dr. Simon Kerry, CEO, Karus Therapeutics
  • 11.3. Dr. James Christensen, CSO and Senior VP, Mirati Therapeutics
  • 11.4. Dr. Hyung J. Chun, MD, FAHA, Associate Professor of Medicine, Yale School of Medicine

12. APPENDIX 1: TABULATED DATA

13. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures:

  • Figure 3.1: Central Dogma of Molecular Biology
  • Figure 3.2: Stages of the Cell Cycle
  • Figure 3.3: DNA Packaging: Key Steps
  • Figure 3.4: Key Epigenetic Mechanisms
  • Figure 3.5: Effects of HATs and HDACs on Chromatin Structure
  • Figure 3.6: Classification of HDACs
  • Figure 3.7: Role of HDACs in Regulation of Cellular Processes
  • Figure 3.8: Role of HDAC and HDAC Inhibitors in DNA Damage Repair
  • Figure 3.9: Role of HDAC and HDAC Inhibitors in Apoptosis
  • Figure 3.10: Role of HDAC and HDAC Inhibitors in Metabolism and Senescence
  • Figure 3.11: HDAC Inhibitors: Pharmacophore Model
  • Figure 3.12: Classification of HDAC Inhibitors
  • Figure 3.13: HDAC Inhibitors: Target Disease Areas
  • Figure 3.14: Role of HDACs in Cancer
  • Figure 3.15: Role of HDAC Inhibitors in Cardiovascular Disorders
  • Figure 4.1: HDAC Inhibitors: Distribution by Phase of Development
  • Figure 4.2: HDAC Inhibitors: Distribution by Therapeutic Area
  • Figure 4.3: HDAC Inhibitors: Distribution by HDAC Class Specificity
  • Figure 4.4: HDAC Inhibitors: Distribution by Type of Developer
  • Figure 4.5: HDAC Inhibitors: Distribution by Geography
  • Figure 4.6: HDAC Inhibitors: Regional Landscape
  • Figure 4.7: HDAC Inhibitors: Active Industry Players
  • Figure 5.1: Celgene Corporation: Annual Revenues, 2011-2015 (USD Billion)
  • Figure 5.2: Istodax®: Mechanism of Action
  • Figure 5.3: Istodax®: Annual Revenues, 2011-2015 (USD Million)
  • Figure 5.4: Beleodaq®: Quarterly Revenues, 2014-2015 (USD Million)
  • Figure 5.5: Novartis: Annual Revenues, 2011-2015 (USD Billion)
  • Figure 5.6: Novartis Annual Revenues, 2015: Distribution by Business Segments (USD Billion)
  • Figure 5.7: Syndax Pharmaceuticals: Funding, 2007-2015 (USD Million)
  • Figure 6.1: HDAC Inhibitors Analysis: Distribution by Target HDAC Class and Therapeutic Areas
  • Figure 6.2: HDAC Inhibitors Grid Analysis: Distribution by Target HDAC Class, Therapeutic Area and Phase of Development
  • Figure 6.3: HDAC Inhibitors Landscape Analysis: Distribution by Developer and Phase of Development
  • Figure 7.1: Overall HDAC Inhibitors Market (USD Million): 2016-2026 (Base Scenario)
  • Figure 7.2: HDAC Inhibitors: Market Distribution on Basis of Therapeutic Area, 2026 (USD Million)
  • Figure 7.3: HDAC Inhibitors: Market Distribution on Basis of Class Specificity, 2016, 2026 (USD Million)
  • Figure 7.4: HDAC Inhibitors: Distribution of Market Share, 2016, 2026 (USD Million)
  • Figure 7.5: Istodax® Sales Forecast (USD Million): 2016-2026 (Base Scenario)
  • Figure 7.6: Beleodaq® Sales Forecast (USD Million): 2016-2026 (Base Scenario)
  • Figure 7.7: Farydak® Sales Forecast (USD Million): 2016-2026 (Base Scenario)
  • Figure 7.8: Epidaza® Sales Forecast (USD Million): 2016-2026 (Base Scenario)
  • Figure 7.9: Entinostat Sales Forecast (USD Million): 2016-2026 (Base Scenario)
  • Figure 7.10: Abexinostat Sales Forecast (USD Million): 2016-2026 (Base Scenario)
  • Figure 7.11: CUDC-907 Sales Forecast (USD Million): 2016-2026 (Base Scenario)
  • Figure 7.12: FRM-0334 Sales Forecast (USD Million): 2016-2026 (Base Scenario)
  • Figure 7.13: Mocetinostat Sales Forecast (USD Million): 2016-2026 (Base Scenario)
  • Figure 7.14: Pracinostat Sales Forecast (USD Million): 2016-2026 (Base Scenario)
  • Figure 7.15: Resminostat Sales Forecast (USD Million): 2016-2026 (Base Scenario)
  • Figure 7.16: SFX-01 Sales Forecast (USD Million): 2016-2026 (Base Scenario)
  • Figure 7.17: SHP-141 Sales Forecast (USD Million): 2016-2026 (Base Scenario)
  • Figure 7.18: Tefinostat Sales Forecast (USD Million): 2016-2026 (Base Scenario)
  • Figure 8.1: Publication Analysis: Quarterly Distribution (2014-2015)
  • Figure 8.2: Publication Analysis: Distribution by HDAC Inhibitor Class
  • Figure 8.3: Publication Analysis: Distribution by Drugs Studied
  • Figure 8.4: Publication Analysis: Distribution by Therapeutic Area
  • Figure 8.5: Publication Analysis: Distribution by Journals
  • Figure 8.6: Publication Analysis: Distribution by Phase of Development
  • Figure 8.7: Publication Analysis: Distribution by Therapies Studied
  • Figure 9.1: HDAC Inhibitors Social Media Analysis: Twitter Trend, 2009-2015
  • Figure 9.2: HDAC Inhibitors Social Media Analysis: Twitter, Most Popular Words, 2009-2015
  • Figure 9.3: HDAC Inhibitors Social Media Analysis: Facebook Trend, 2009-2015
  • Figure 10.1: HDAC Inhibitors Market Summary (USD Million): 2016, 2021, 2026

List of Tables:

  • Table 3.1: Histone Modification: Classification
  • Table 3.2: Transcription: Effect of Histone Modifications
  • Table 3.3: DNA Repair: Effect of Histone Modifications
  • Table 3.4: Euchromatin and Heterochromatin: Characteristic Features
  • Table 3.5: Zn2+ Dependent HDACs: Properties
  • Table 3.6: NAD+ Dependent HDACs: Properties
  • Table 3.7: Non-Histone Substrates of HDACs
  • Table 3.8: HDACs: Miscellaneous Functions
  • Table 3.9: HDAC Inhibitors: Natural and Synthetic
  • Table 3.10: Neurodegenerative Disorders: Epigenetic Changes
  • Table 4.1: HDAC Inhibitors: Development Pipeline
  • Table 5.1: HDAC Inhibitors: Marketed and Phase III Molecules
  • Table 5.2: Istodax®: Current Status of Development
  • Table 5.3: Istodax®: Clinical Trials
  • Table 5.4: Beleodaq®: Current Status of Development
  • Table 5.5: Beleodaq®: Clinical Trials
  • Table 5.6: Farydak®: Current Status of Development
  • Table 5.7: Farydak®: Clinical Trials
  • Table 5.8: Farydak®: Response Rate (Multiple Myeloma)
  • Table 5.9: Epidaza®: Current Status of Development
  • Table 5.10: Epidaza®: Clinical Trials
  • Table 5.11: Entinostat: Current Status of Development
  • Table 5.12: Entinostat: Clinical Trials
  • Table 5.13: Entinostat: List of Abstracts (2011-2016)
  • Table 5.14: HDAC Inhibitors: Phase II Molecules
  • Table 5.15: Abexinostat: Current Status of Development
  • Table 5.16: Abexinostat: Clinical Trials
  • Table 5.17: CUDC-907: Current Status of Development
  • Table 5.18: CUDC-907: Clinical Trials
  • Table 5.19: FRM-0334: Current Status of Development
  • Table 5.20: FRM-0334: Clinical Trials
  • Table 5.21: Givinostat: Current Status of Development
  • Table 5.22: Givinostat: Clinical Trials
  • Table 5.23: Mocetinostat: Current Status of Development
  • Table 5.24: Mocetinostat: Clinical Trials
  • Table 5.25: Pracinostat: Current Status of Development
  • Table 5.26: Pracinostat: Clinical Trials
  • Table 5.27: Resminostat: Current Status of Development
  • Table 5.28: Resminostat: Clinical Trials
  • Table 5.29: SFX-01: Current Status of Development
  • Table 5.30: SFX-01: Clinical Trials
  • Table 5.31: SFX-01: Preclinical Collaborations
  • Table 5.32: SHP-141: Current Status of Development
  • Table 5.33: SHP-141: Clinical Trials
  • Table 5.34: Tefinostat: Current Status of Development
  • Table 5.35: Tefinostat: Clinical Trials
  • Table 6.1: HDAC Inhibitors Endpoint Analysis: Primary Endpoints (Oncological Disorders)
  • Table 6.2: HDAC Inhibitors Endpoint Analysis: Secondary Endpoints (Oncological Disorders)
  • Table 6.3: HDAC Inhibitors Endpoint Analysis: Other Endpoints (Oncological Disorders)
  • Table 6.4: HDAC Inhibitors Endpoint Analysis: Non-Oncological Disorders
  • Table 7.1: HDAC Inhibitors: Potential Candidates
  • Table 7.2: Istodax®: Target Patient Population
  • Table 7.3: Beleodaq®: Target Patient Population
  • Table 7.4: Farydak®: Target Patient Population
  • Table 7.5: Epidaza®: Target Patient Population
  • Table 7.6: Entinostat: Target Patient Population
  • Table 7.7: Abexinostat: Target Patient Population
  • Table 7.8: CUDC-907: Target Patient Population
  • Table 7.9: FRM-0334: Target Patient Population
  • Table 7.10: Mocetinostat: Target Patient Population
  • Table 7.11: Pracinostat: Target Patient Population
  • Table 7.12: Resminostat: Target Patient Population
  • Table 7.13: SFX-01: Target Patient Population
  • Table 7.14: SHP-141: Target Patient Population
  • Table 7.15: Tefinostat: Target Patient Population
  • Table 8.1: HDAC Inhibitors: Publications (2014, 2015)
  • Table 12.1: HDAC Inhibitors: Distribution by Phase of Development
  • Table 12.2: HDAC Inhibitors: Distribution by Therapeutic Area
  • Table 12.3: HDAC Inhibitors: Distribution by Class Specificity
  • Table 12.4: HDAC Inhibitors: Distribution by Type of Developer
  • Table 12.5: HDAC Inhibitors: Distribution by Geography
  • Table 12.6: HDAC Inhibitors: Active Industry Players
  • Table 12.7: Celgene Corporation: Annual Revenues, 2011-2015 (USD Million)
  • Table 12.8: Istodax®: Annual Revenues, 2011-2015 (USD Million)
  • Table 12.9: Beleodaq®: Quarterly Revenues, 2014-2015 (USD Million)
  • Table 12.10: Novartis: Annual Revenues, 2011-2015 (USD Million)
  • Table 12.11: Novartis Annual Revenues, 2015: Distribution by Business Segments (USD Million)
  • Table 12.12: Syndax Pharmaceuticals: Funding, 2007-2015 (USD Million)
  • Table 12.13: Overall HDAC Inhibitors Market (USD Million): 2016-2026 (Base Scenario)
  • Table 12.14: HDAC Inhibitors: Market Distribution on Basis of Therapeutic Area, 2026 (USD Million)
  • Table 12.15: HDAC Inhibitors: Market Distribution on Basis of Class Specificity, 2026 (USD Million)
  • Table 12.16: HDAC Inhibitors: Distribution of Market Share, 2016 (USD Million)
  • Table 12.17: HDAC Inhibitors: Distribution of Market Share, 2026 (USD Million)
  • Table 12.18: Istodax® Sales Forecast (USD Million), 2016-2021 (Base Scenario)
  • Table 12.19: Istodax® Sales Forecast (USD Million), 2016-2021 (Optimistic Scenario)
  • Table 12.20: Istodax® Sales Forecast (USD Million), 2016-2021 (Conservative Scenario)
  • Table 12.21: Beleodaq® Sales Forecast (USD Million), 2016-2021 (Base Scenario)
  • Table 12.22: Beleodaq® Sales Forecast (USD Million), 2016-2021 (Optimistic Scenario)
  • Table 12.23: Beleodaq® Sales Forecast (USD Million), 2016-2021 (Conservative Scenario)
  • Table 12.24: Farydak® Sales Forecast (USD Million), 2016-2021 (Base Scenario)
  • Table 12.25: Farydak® Sales Forecast (USD Million), 2016-2021 (Optimistic Scenario)
  • Table 12.26: Farydak® Sales Forecast (USD Million), 2016-2021 (Conservative Scenario)
  • Table 12.27: Epidaza® Sales Forecast (USD Million), 2016-2021 (Base Scenario)
  • Table 12.28: Epidaza® Sales Forecast (USD Million), 2016-2021 (Optimistic Scenario)
  • Table 12.29: Epidaza® Sales Forecast (USD Million), 2016-2021 (Conservative Scenario)
  • Table 12.30: Entinostat Sales Forecast (USD Million), 2016-2021 (Base Scenario)
  • Table 12.31: Entinostat Sales Forecast (USD Million), 2016-2021 (Optimistic Scenario)
  • Table 12.32: Entinostat Sales Forecast (USD Million), 2016-2021 (Conservative Scenario)
  • Table 12.33: Pracinostat Sales Forecast (USD Million), 2016-2021 (Base Scenario)
  • Table 12.34: Pracinostat Sales Forecast (USD Million), 2016-2021 (Optimistic Scenario)
  • Table 12.35: Pracinostat Sales Forecast (USD Million), 2016-2021 (Conservative Scenario)
  • Table 12.36: Resminostat Sales Forecast (USD Million), 2016-2021 (Base Scenario)
  • Table 12.37: Resminostat Sales Forecast (USD Million), 2016-2021 (Optimistic Scenario)
  • Table 12.38: Resminostat Sales Forecast (USD Million), 2016-2021 (Conservative Scenario)
  • Table 12.39: Tefinostat Sales Forecast (USD Million), 2016-2021 (Base Scenario)
  • Table 12.40: Tefinostat Sales Forecast (USD Million), 2016-2021 (Optimistic Scenario)
  • Table 12.41: Tefinostat Sales Forecast (USD Million), 2016-2021 (Conservative Scenario)
  • Table 12.42: SHP-141 Sales Forecast (USD Million), 2016-2021 (Base Scenario)
  • Table 12.43: SHP-141 Sales Forecast (USD Million), 2016-2021 (Optimistic Scenario)
  • Table 12.44: SHP-141 Sales Forecast (USD Million), 2016-2021 (Conservative Scenario)
  • Table 12.45: FRM-0334 Sales Forecast (USD Million), 2016-2021 (Base Scenario)
  • Table 12.46: FRM-0334 Sales Forecast (USD Million), 2016-2021 (Optimistic Scenario)
  • Table 12.47: FRM-0334 Sales Forecast (USD Million), 2016-2021 (Conservative Scenario)
  • Table 12.48: SFX-01 Sales Forecast (USD Million), 2016-2021 (Base Scenario)
  • Table 12.49: SFX-01 Sales Forecast (USD Million), 2016-2021 (Optimistic Scenario)
  • Table 12.50: SFX-01 Sales Forecast (USD Million), 2016-2021 (Conservative Scenario)
  • Table 12.51: CUDC-907 Sales Forecast (USD Million), 2016-2021 (Base Scenario)
  • Table 12.52: CUDC-907 Sales Forecast (USD Million), 2016-2021 (Optimistic Scenario)
  • Table 12.53: CUDC-907 Sales Forecast (USD Million), 2016-2021 (Conservative Scenario)
  • Table 12.54: Mocetinostat Sales Forecast (USD Million), 2016-2021 (Base Scenario)
  • Table 12.55: Mocetinostat Sales Forecast (USD Million), 2016-2021 (Optimistic Scenario)
  • Table 12.56: Mocetinostat Sales Forecast (USD Million), 2016-2021 (Conservative Scenario)
  • Table 12.57: Abexinostat Sales Forecast (USD Million), 2016-2021 (Base Scenario)
  • Table 12.58: Abexinostat Sales Forecast (USD Million), 2016-2021 (Optimistic Scenario)
  • Table 12.59: Abexinostat Sales Forecast (USD Million), 2016-2021 (Conservative Scenario)
  • Table 12.60: Publication Analysis: Quarterly Distribution (2014-2015)
  • Table 12.61: Publication Analysis: Distribution by HDAC Inhibitor Class
  • Table 12.62: Publication Analysis: Distribution by Drugs Studied
  • Table 12.63: Publication Analysis: Distribution by Therapeutic Area
  • Table 12.64: Publication Analysis: Distribution by Journals
  • Table 12.65: Publication Analysis: Distribution by Phase of Development
  • Table 12.66: Publication Analysis: Distribution by Therapies Studied
  • Table 12.67: HDAC Inhibitors Market Summary (USD Million): 2016, 2021, 2026

Listed Companies

The following companies and organizations have been mentioned in the report.

  • 1. 4SC
  • 2. AACR
  • 3. AbbVie
  • 4. Acceleron Pharma
  • 5. Acetylon Pharmaceuticals
  • 6. Active Biotech
  • 7. Agios Pharmaceuticals
  • 8. ASH
  • 9. Arno Therapeutics
  • 10. Astellas Pharma
  • 11. Bayer Schering Pharma
  • 12. Baylor College of Medicine
  • 13. BioMarin
  • 14. Bionor Immuno
  • 15. bluebird bio
  • 16. Case Comprehensive Cancer Center
  • 17. Celera Genomics
  • 18. Celgene
  • 19. Celleron Therapeutics
  • 20. Centre de Recherche en Cancérologie
  • 21. CETYA Therapeutics
  • 22. CHDI Foundation
  • 23. Chipscreen Biosciences
  • 24. Chong Kun Dang Pharmaceutical
  • 25. Chroma Therapeutics
  • 26. Croix-Rousse Hospital
  • 27. CrystalGenomics
  • 28. Curis
  • 29. DAC
  • 30. Diaxonhit
  • 31. DNA Therapeutics
  • 32. Duke University
  • 33. ECOG-ACRIN Cancer Research Group
  • 34. Eddingpharm
  • 35. Eisai
  • 36. Epizyme
  • 37. Errant Gene Therapeutics
  • 38. European Calcified Tissue Society
  • 39. Evgen Pharma
  • 40. FORMA Therapeutics
  • 41. FORUM Pharmaceuticals
  • 42. Fudan University
  • 43. Genentech
  • 44. Genextra
  • 45. Gilead
  • 46. Gloucester Pharmaceuticals
  • 47. GNT Biotech
  • 48. GSK
  • 49. Harvard Medical School
  • 50. Henan Cancer Hospital
  • 51. HUYA Biosciences
  • 52. Ikerchem
  • 53. Imperial College London
  • 54. In2Gen
  • 55. International Bone and Mineral Society
  • 56. Israel Cancer Association and Bar Ilan University
  • 57. Italfarmaco
  • 58. Johnson and Johnson
  • 59. Kalypsys
  • 60. Karus Therapeutics
  • 61. King's College, University of London
  • 62. Kyoto Prefectural University of Medicine
  • 63. Kyoto University
  • 64. Kyowa Hakko Kirin
  • 65. Leukemia and Lymphoma Society
  • 66. Lymphoma Academic Research Organization
  • 67. Massachusetts General Hospital
  • 68. Mayo Clinic
  • 69. MedImmune
  • 70. MEI Pharma
  • 71. Memorial Sloan-Kettering Cancer Center
  • 72. Menarini
  • 73. Merck
  • 74. MethylGene
  • 75. Mirati Therapeutics
  • 76. Morphosys
  • 77. Mundipharma-EDO
  • 78. National Brain Research Centre
  • 79. National Comprehensive Cancer Network
  • 80. National Taiwan University
  • 81. NCI
  • 82. Novartis
  • 83. NuPotential
  • 84. Oceanyx Pharma
  • 85. Oncolys Biopharma
  • 86. Onxeo
  • 87. Onyx
  • 88. Orchid Pharma
  • 89. Paterson Institute for Cancer Research
  • 90. Pfizer
  • 91. Pharmacyclics
  • 92. Pharmion Corporation
  • 93. Quimatryx
  • 94. Quintiles
  • 95. Repligen
  • 96. Respiratorius
  • 97. Roche
  • 98. Rodin Therapeutics
  • 99. Royal Veterinary College, University of London
  • 100. Ruijin Hospital
  • 101. S*Bio
  • 102. Sarcoma Alliance for Research through Collaboration
  • 103. Seattle Genetics
  • 104. Servier Canada
  • 105. Shape Pharmaceuticals
  • 106. Sidney Kimmel Comprehensive Cancer Center
  • 107. Sigma Tau Pharmaceuticals
  • 108. Signal Rx
  • 109. SpeBio
  • 110. Spectrum Pharmaceuticals
  • 111. Stanley Center for Psychiatric Research
  • 112. Sutro Biopharma
  • 113. Syndax Pharmaceuticals
  • 114. Synovo GmbH
  • 115. Taipei Medical University
  • 116. TetraLogic Pharmaceuticals
  • 117. University of Liverpool
  • 118. University of Messina
  • 119. University of Miami
  • 120. Vanderbilt University School of Medicine
  • 121. Ventana Medical Systems
  • 122. Vilnius University
  • 123. Yakult Honsha
  • 124. Yale University
  • 125. Yonsei University College of Medicine
Back to Top